驱动基因阳性人群TKI治疗新的策略.pptVIP

P-AVS-2018.09-109 Valid Until 2020. 09 驱动基因阳性人群TK治疗新策略 本资科仅代表个人观,在促进字木信的沟和交流。处方语茶帝国家食品药邑监督色理总同批佳的药昂说明 仅供医疗卫生专业人十考 2004年EGFR突变的发现和验证 就此拉开了 nSCLc靶向精准治疗新时代 The NEW ENGLAND JOURNAL Of MEDICINE Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell gooD3Dp比556计=aD Jeffrey G Supko, Pn. D, Frank G. Halusaa, M, D. Ph. D,, Daed N. Louis M Jeff Settleman, Ph. D, and Danie A. Haber, M.D., Ph D 迄今非鳞 nSCLC的精准治疔策略已取得爆发式发展 HER2 ALK HER2 2% ROS1 2% BRAF 2% RET 2. Rociletinibs MEK1 1% Tsao As, et al. J Thorac oncol 201 6 May: 11(5): 613-38 当前EGF突变一线治疗的现状和局限